How an approach called 'shock and kill' could cure HIV

December 1, 2015 by Jyoti Madhusoodanan
How an approach called ‘shock and kill’ could cure HIV
Scanning electromicrograph of an HIV-infected H9 T-cell. Credit: NIAID

Current HIV medications can effectively prevent the disease's progression, but the virus can lurk for a lifetime in the body.

By integrating into the genome of , known as memory T cells, HIV stays hidden as a piece of DNA in cellular reservoirs that drugs find difficult to destroy.

While patients on anti-retroviral therapy (ART) won't develop full-blown AIDS, lurking HIV can lead to more insidious effects such as accelerated aging, heart attacks or diabetes that start earlier in life than people without HIV and other inflammatory dysfunctions. And if therapy is interrupted, this latent reservoir awakens, makes viral copies and can infect more cells.

Although scientists have known about the reservoir for years, early research and clinical efforts were focused on improving ART to thwart AIDS symptoms and rapid deaths. As ART has improved, researchers can now focus on eradicating the disease. "We can finally talk about the idea of a cure without raising laughs," says Mike McCune, MD, PhD, chief of the Department of Experimental Medicine at UCSF.

To truly cure patients, scientists are trying to find ways to target the HIV reservoir in a strategy known as "shock and kill." The Foundation for AIDS Research's (amfAR) $20 million grant to seek a cure for HIV aims to accomplish four broad goals: chart, understand, record and eradicate elusive reservoirs of HIV-harboring T cells.

"It's difficult because you can't leave even a single cell standing – you have to get every last latent cell," says Steven Deeks, MD, a UCSF professor of medicine who is one of four project directors leading each aspect of the grant.

Finding Where HIV is Hiding

HIV can only infect cells that express a marker named CD4 that's found on some kinds of T cells and macrophages. But only 3 to 5 percent of CD4 T cells circulate in blood. The rest typically live in organs such as the brain, lymph nodes, gut, female reproductive tract and other locations.

"When we give ART, we knock out the circulating virus but we don't knock out these cells residing in organs," says McCune, whose team will find out where HIV hides in the body. "All these organs represent the immune system, and it's important to understand where in that system the virus lives and in what state."

Charting precisely where latent cells linger is the first step to eliminating them, explains McCune. The locations of reservoirs may differ in patients based on an individual's gender, race, age, the length of time they've had an HIV infection and other factors.

Once a reservoir is spotted, scientists also will need tools to track whether a "shock" agent has actually activated latent cells. For now, clinicians rely on measuring viral RNA circulating in plasma. But these tests don't measure the miniscule levels of virus that lurk in reservoirs. To track these tiny quantities, researchers are developing advanced tools that can home in on HIV in the genome of a single latent T cell.

"In a patient on suppressive anti-retroviral therapy, it's very hard to even find the virus. One of the main challenges is to develop really sensitive methods," says Satish Pillai, PhD, associate director of the UCSF-GIVI Center For AIDS Research (CFAR). "As part of the amfAR grant, we're figuring out how to use cutting-edge imaging methods that are non-invasive so we can visualize the reservoir in tissues."

A Combination of Attack Plans

Once scientists are able to find and track latent HIV, eliminating the reservoir will require a combination of attack plans, Deeks explains.

One tactic they'll explore is immunotherapy, or activating the body's immune system to better fight the infection using toll-like receptors, known as TLRs. Previous studies of HIV's counterpart in primates have reported that the use of TLR agonists in a shock-and-kill tactic can reduce the size of the latent reservoir.

In a collaborative effort that spans multiple institutions nationwide, the researchers also will deliver TLR agonists using nano-sized capsules of fat to cells. Once triggered with TLR agonists, immune can be deployed against the virus with an HIV vaccine.

Even before the notion of "shock and kill" becomes clinical reality, a multi-pronged approach is likely to be critical to clearing and controlling the HIV reservoir, says Deeks.

"I'm a firm believer that we need to reduce the size of the reservoir to improve patients' health," he adds. "These strategies all go hand-in-hand. It's a balance because you want to turn the immune system on to get the virus out, but you don't want to trigger a massive inflammatory response."

By bringing together basic scientists and clinical researchers, Deeks says the aim is to translate research findings quickly into real improvements for people living with HIV.

"We're not so much focused on the basic discovery in itself," says Deeks. "It's a means to an end – the real goal is to help these patients. Although we're an academic group, we're really focused on developing therapies."

Explore further: Targeting HIV 'reservoir' could be first step to understanding how to cure the disease

Related Stories

Targeting HIV 'reservoir' could be first step to understanding how to cure the disease

December 1, 2015
A new clinical trial will test whether it is possible to destroy hidden reservoirs of HIV virus that are a key obstacle to curing the disease.

Towards elimination of HIV reservoirs

November 5, 2015
Current antiretroviral therapy can keep HIV in check and prevent AIDS in the vast majority of treated patients. However, as it is unable to eliminate viral reservoirs and cure the infection, patients need to stay on the life-long ...

Cancer drug promises to break down barrier to HIV cure

September 18, 2015
Researchers have found a promising way of kicking the AIDS virus out of its hiding place in infected cells, potentially removing the main obstacle to curing HIV.

A potential role for fat tissue as an HIV reservoir and source of chronic inflammation

September 24, 2015
Viral persistence and chronic inflammation are two key features of HIV-positive patients on antiretroviral therapy (ART). A study published on September 24th in PLOS Pathogens reports results from macaques and humans that ...

HIV grows despite treatment, study finds

August 4, 2015
HIV can continue to grow in patients who are thought to be responding well to treatment, according to research by the University of Liverpool.

Identification of drug combinations that reverse HIV-1 latency

March 30, 2015
There are almost 40 million people throughout the world living with HIV-1/AIDs. While current antiretroviral therapies are able to reduce the amount of virus in the blood, HIV remains present in a latent state within T cells. ...

Recommended for you

Three-in-one antibody protects monkeys from HIV-like virus

September 20, 2017
A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers ...

Fighting HIV on multiple fronts might lead to vaccine

September 20, 2017
A combination antibody strategy could be the key to halting the spread of HIV, according to results from two promising animal studies.

HIV-AIDS: Following your gut

September 18, 2017
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have discovered a way to slow viral replication in the gastrointestinal tract of people infected by HIV-AIDS.

Study finds cutbacks in foreign aid for HIV treatment would cause great harm

August 30, 2017
Proposed reductions in U.S. foreign aid would have a devastating impact on HIV treatment and prevention programs in countries receiving such aid, an international team of investigators reports. In their paper published online ...

Cancer drug can reactivate HIV

August 24, 2017
People living with HIV must take a combination of three or more different drugs every day for the rest of their lives. Unfortunately, by following this strict treatment plan, they can suffer from side effects ranging from ...

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.